Please enable JavaScript to continue using this application.

Compare $KROS vs $QTTB | Chartloom

Compare

$KROS vs $QTTB

Keros Therapeutics Inc · Q32 Bio Inc

KROS

Keros Therapeutics Inc

QTTB

Q32 Bio Inc

Compare $KROS vs $QTTB

Comparing Keros Therapeutics Inc and Q32 Bio Inc

KROSKeros Therapeutics Inc

QTTBQ32 Bio Inc

KROSKeros Therapeutics Inc

Market cap

$236M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-93.6%

YTD performance

-35.5%

52W performance

-25.1%

FCF yield

-20.5%

QTTBQ32 Bio Inc

Market cap

$248M

P/E (TTM)

8.22x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

142.4%

52W performance

178.9%

FCF yield

-8.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

KROS

QTTB

Detailed metrics comparison

KROS

Keros Therapeutics Inc

QTTB

Q32 Bio Inc

Market Cap

KROS$236M

QTTB$248M

Enterprise Value

KROS$-21M

QTTB$142M

Price

KROS$11.95

QTTB$8.34

P/E Ratio

KROSN/A

QTTB8.22x

P/S Ratio

KROS15.75x

QTTB4.62x

EV/Sales

KROS-1.41x

QTTB2.64x

EV/EBITDA

KROS-0.47x

QTTB3.69x

P/B Ratio

KROS0.86x

QTTB2.31x

P/FCF Ratio

KROSN/A

QTTBN/A

EV/FCF

KROS0.44x

QTTB-7.16x

PEG Ratio

KROSN/A

QTTBN/A

Forward P/E (NTM)

KROSN/A

QTTBN/A

Forward P/S (NTM)

KROSN/A

QTTBN/A

Revenue (TTM)

KROS$15M

QTTB$54M

Revenue Growth (YoY)

KROS-93.6%

QTTBN/A

Forward Rev Growth

KROS-96.3%

QTTB215.1%

Gross Margin (TTM)

KROS0.0%

QTTB0.0%

Operating Margin (TTM)

KROS0.0%

QTTB85.4%

EBITDA Margin (TTM)

KROS-665.2%

QTTB71.6%

Net Margin (TTM)

KROS-553.9%

QTTB93.7%

FCF Margin (TTM)

KROS-322.9%

QTTB-36.9%

Net Income (TTM)

KROS$-83M

QTTB$50M

FCF (TTM)

KROS$-48M

QTTB$-20M

EPS (TTM)

KROS-$4.20

QTTB$0.00

ROE (TTM)

KROS-2140.0%

QTTB137.4%

ROA (TTM)

KROS-1979.0%

QTTB45.1%

ROIC (TTM)

KROS-2140.0%

QTTB111.6%

Cash

KROS$258M

QTTB$106M

Debt

KROS$0

QTTB$0

Net Cash/Debt

KROS$258M

QTTB$106M

Current Ratio (TTM)

KROS21.96x

QTTB20.30x

Quick Ratio (TTM)

KROS21.53x

QTTB19.80x

Debt/Equity (TTM)

KROS0.00x

QTTB2.29x

Debt/Assets (TTM)

KROS0.0%

QTTB0.0%

Interest Coverage (TTM)

KROSN/A

QTTBN/A

Net Debt/EBITDA (TTM)

KROS0.00x

QTTB0.00x

Beta

KROS1.20

QTTB0.50

52W Performance

KROS-25.1%

QTTB178.9%

YTD Performance

KROS-35.5%

QTTB142.4%

% from 52W High

KROS-47.0%

QTTB-64.6%

% from 52W Low

KROS23.3%

QTTB337.8%

Asset Turnover (TTM)

KROS0.06x

QTTB0.87x

FCF Yield (TTM)

KROS-20.5%

QTTB-8.0%

Earnings Yield (TTM)

KROS-35.2%

QTTB20.3%

Dividend Yield (TTM)

KROSN/A

QTTBN/A

Rule of 40

KROS-416.5

QTTB-36.9

EV/GP/RG

KROSN/A

QTTBN/A

Ticker research

View KROS research View QTTB research

Metric	KROS Keros Therapeutics Inc	QTTB Q32 Bio Inc
Market & Valuation
Market Cap	$236M	$248M
Enterprise Value	$-21M	$142M
Price	$11.95	$8.34
P/E Ratio	N/A	8.22x
P/S Ratio	15.75x	4.62x
EV/Sales	-1.41x	2.64x
EV/EBITDA	-0.47x	3.69x
P/B Ratio	0.86x	2.31x
P/FCF Ratio	N/A	N/A
EV/FCF	0.44x	-7.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$15M	$54M
Revenue Growth (YoY)	-93.6%	N/A
Forward Rev Growth	-96.3%	215.1%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	85.4%
EBITDA Margin (TTM)	-665.2%	71.6%
Net Margin (TTM)	-553.9%	93.7%
FCF Margin (TTM)	-322.9%	-36.9%
Net Income (TTM)	$-83M	$50M
FCF (TTM)	$-48M	$-20M
EPS (TTM)	-$4.20	$0.00
ROE (TTM)	-2140.0%	137.4%
ROA (TTM)	-1979.0%	45.1%
ROIC (TTM)	-2140.0%	111.6%
Financial Health
Cash	$258M	$106M
Debt	$0	$0
Net Cash/Debt	$258M	$106M
Current Ratio (TTM)	21.96x	20.30x
Quick Ratio (TTM)	21.53x	19.80x
Debt/Equity (TTM)	0.00x	2.29x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	0.50
52W Performance	-25.1%	178.9%
YTD Performance	-35.5%	142.4%
% from 52W High	-47.0%	-64.6%
% from 52W Low	23.3%	337.8%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.87x
FCF Yield (TTM)	-20.5%	-8.0%
Earnings Yield (TTM)	-35.2%	20.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-416.5	-36.9
EV/GP/RG	N/A	N/A
Ticker research	View KROS research	View QTTB research

Valuation

P/E Ratio

QTTB

8.22x

P/S Ratio

QTTB

4.62x

KROS

15.75x

EV/FCF

QTTB

-7.16x

KROS

0.44x

Growth & revenue

Revenue Growth TTM

KROS

-93.6%

Forward Revenue Growth

QTTB

215.1%

KROS

-96.3%

Profitability & performance

Gross Margin

KROS

0.0%

QTTB

0.0%

ROE

QTTB

137.4%

KROS

-2140.0%

FCF Yield %

QTTB

-8.0%

KROS

-20.5%

52-Week Performance

QTTB

178.9%

KROS

-25.1%

Detailed metrics comparison

KROS

Keros Therapeutics Inc

QTTB

Q32 Bio Inc

Market Cap

KROS$236M

QTTB$248M

Enterprise Value

KROS$-21M

QTTB$142M

Price

KROS$11.95

QTTB$8.34

P/E Ratio

KROSN/A

QTTB8.22x

P/S Ratio

KROS15.75x

QTTB4.62x

EV/Sales

KROS-1.41x

QTTB2.64x

EV/EBITDA

KROS-0.47x

QTTB3.69x

P/B Ratio

KROS0.86x

QTTB2.31x

P/FCF Ratio

KROSN/A

QTTBN/A

EV/FCF

KROS0.44x

QTTB-7.16x

PEG Ratio

KROSN/A

QTTBN/A

Forward P/E (NTM)

KROSN/A

QTTBN/A

Forward P/S (NTM)

KROSN/A

QTTBN/A

Revenue (TTM)

KROS$15M

QTTB$54M

Revenue Growth (YoY)

KROS-93.6%

QTTBN/A

Forward Rev Growth

KROS-96.3%

QTTB215.1%

Gross Margin (TTM)

KROS0.0%

QTTB0.0%

Operating Margin (TTM)

KROS0.0%

QTTB85.4%

EBITDA Margin (TTM)

KROS-665.2%

QTTB71.6%

Net Margin (TTM)

KROS-553.9%

QTTB93.7%

FCF Margin (TTM)

KROS-322.9%

QTTB-36.9%

Net Income (TTM)

KROS$-83M

QTTB$50M

FCF (TTM)

KROS$-48M

QTTB$-20M

EPS (TTM)

KROS-$4.20

QTTB$0.00

ROE (TTM)

KROS-2140.0%

QTTB137.4%

ROA (TTM)

KROS-1979.0%

QTTB45.1%

ROIC (TTM)

KROS-2140.0%

QTTB111.6%

Cash

KROS$258M

QTTB$106M

Debt

KROS$0

QTTB$0

Net Cash/Debt

KROS$258M

QTTB$106M

Current Ratio (TTM)

KROS21.96x

QTTB20.30x

Quick Ratio (TTM)

KROS21.53x

QTTB19.80x

Debt/Equity (TTM)

KROS0.00x

QTTB2.29x

Debt/Assets (TTM)

KROS0.0%

QTTB0.0%

Interest Coverage (TTM)

KROSN/A

QTTBN/A

Net Debt/EBITDA (TTM)

KROS0.00x

QTTB0.00x

Beta

KROS1.20

QTTB0.50

52W Performance

KROS-25.1%

QTTB178.9%

YTD Performance

KROS-35.5%

QTTB142.4%

% from 52W High

KROS-47.0%

QTTB-64.6%

% from 52W Low

KROS23.3%

QTTB337.8%

Asset Turnover (TTM)

KROS0.06x

QTTB0.87x

FCF Yield (TTM)

KROS-20.5%

QTTB-8.0%

Earnings Yield (TTM)

KROS-35.2%

QTTB20.3%

Dividend Yield (TTM)

KROSN/A

QTTBN/A

Rule of 40

KROS-416.5

QTTB-36.9

EV/GP/RG

KROSN/A

QTTBN/A

Ticker research

View KROS research View QTTB research

Metric	KROS Keros Therapeutics Inc	QTTB Q32 Bio Inc
Market & Valuation
Market Cap	$236M	$248M
Enterprise Value	$-21M	$142M
Price	$11.95	$8.34
P/E Ratio	N/A	8.22x
P/S Ratio	15.75x	4.62x
EV/Sales	-1.41x	2.64x
EV/EBITDA	-0.47x	3.69x
P/B Ratio	0.86x	2.31x
P/FCF Ratio	N/A	N/A
EV/FCF	0.44x	-7.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$15M	$54M
Revenue Growth (YoY)	-93.6%	N/A
Forward Rev Growth	-96.3%	215.1%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	85.4%
EBITDA Margin (TTM)	-665.2%	71.6%
Net Margin (TTM)	-553.9%	93.7%
FCF Margin (TTM)	-322.9%	-36.9%
Net Income (TTM)	$-83M	$50M
FCF (TTM)	$-48M	$-20M
EPS (TTM)	-$4.20	$0.00
ROE (TTM)	-2140.0%	137.4%
ROA (TTM)	-1979.0%	45.1%
ROIC (TTM)	-2140.0%	111.6%
Financial Health
Cash	$258M	$106M
Debt	$0	$0
Net Cash/Debt	$258M	$106M
Current Ratio (TTM)	21.96x	20.30x
Quick Ratio (TTM)	21.53x	19.80x
Debt/Equity (TTM)	0.00x	2.29x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	0.50
52W Performance	-25.1%	178.9%
YTD Performance	-35.5%	142.4%
% from 52W High	-47.0%	-64.6%
% from 52W Low	23.3%	337.8%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.87x
FCF Yield (TTM)	-20.5%	-8.0%
Earnings Yield (TTM)	-35.2%	20.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-416.5	-36.9
EV/GP/RG	N/A	N/A
Ticker research	View KROS research	View QTTB research